About  Novogyne

Novogyne Pharmaceuticals is a joint venture between Novartis Pharmaceuticals Corporation of East Hanover, New Jersey and Noven Pharmaceuticals, Inc. of Miami, Florida. Since May 1998, Novogyne has been offering pharmaceutical products that enable physicians to better serve the medical needs of mature women. Novogyne's products include Vivelle-Dot™(estradiol transdermal system), the smallest estrogen patch available, Vivelle® (estradiol) and CombiPatch ® (estradiol/norethindrone acetate transdermal system). With these advanced patches, Novogyne was the first company in the U.S. offering transdermal systems for both the estrogen-only and combination estrogen/progestin markets.

What Do We Offer You?

With the mature woman’s comfort in mind, Novogyne offers the most advanced, and wearable, transdermal patches on the market:

Vivelle-Dot, a postage-stamp-sized advanced generation estrogen patch and the smallest estrogen patch available; and Vivelle (estradiol transdermal system), a half-dollar-sized estrogen patch based on earlier adhesive matrix patch technology.

CombiPatch (estradiol/norethindrone acetate transdermal system), the first combination estrogen/progestin hormone therapy (HT) patch in the U.S.

The Novogyne Advantage

Novogyne’s systems deliver drugs utilizing an adhesive patch containing medication. When adhered to the skin, medication is delivered through the tissues and into the bloodstream over an extended period of time. Most of Novogyne’s patches utilize the patented DOT Matrix™ technology, which allows them to deliver more drug through a smaller patch area than any HT patches. DOT Matrix achieves this without compromising the patch’s ability to adhere. DOT Matrix patches adhere through normal activities, including showering, swimming and exercise.
For more information on the DOT Matrix technology, click here.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT COMBIPATCH (A COMBINATION OF ESTROGEN AND PROGESTIN HORMONES)?

Do not use estrogens and progestins to prevent heart disease, heart attacks, strokes or dementia (decline in memory and thinking skills). Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots, and may increase your risk of dementia.

Do not use CombiPatch if you have had your uterus removed (hysterectomy). CombiPatch should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.

The most common side effects that may occur with CombiPatch are breast pain, vaginal bleeding, and headache.

CombiPatch is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; and treat certain conditions in which a young woman’s ovaries do not produce enough estrogens naturally. If you use CombiPatch only to treat your dryness, itching and burning in or around the vagina, talk with your health care professional about whether a topical vaginal product would be better for you.

You and your health care professional should talk regularly about whether you still need treatment with CombiPatch and whether you are taking the lowest dose that works for you.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT VIVELLE-DOT (AN ESTROGEN HORMONE)?

Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).

Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).

Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.

The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.

Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman’s ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.

You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.

DOT Matrix™ is a trademark of Noven Pharmaceuticals, Inc.


The information contained within this web site is appropriate for U.S. residents only. A visit to this site should not replace a visit to your doctor.

Available by prescription only.

Copyright © 2006 Novogyne Pharmaceuticals. All rights reserved.